Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2020

01-03-2020 | ASO Author Reflections

ASO Author Reflections: Impact of Operative Technique on Anastomotic Failure During Cytoreductive Surgery for Peritoneal Malignancies—Surgeon Preference is Fine

Authors: Jason T. Wiseman, MD, MSPH, Jordan M. Cloyd, MD

Published in: Annals of Surgical Oncology | Issue 3/2020

Login to get access

Excerpt

Anastomotic failure (AF) after gastrointestinal surgery is a dreaded complication and has a reported incidence of 8–12%.1 Extensive efforts have been previously undertaken to explain risk factors for AF in patients with gastrointestinal surgery and the associated sequela of such an event.2,3 However, the incidence of AF, risk factors for its occurrence, and the long-term outcomes of patients with AF following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are poorly understood. Unique to CRS/HIPEC is the administration of HIPEC, which has been previously speculated to increase the incidence and worsen the sequela of AF following CRS. These observations have prompted the operative surgeon to wrestle with the task of strategizing optimal technique to minimize risk of AF. For example, should the surgeon perform a hand-sewn or stapled restorative bowel anastomosis? Should the anastomosis be performed before or after HIPEC? Because few studies have previously investigated factors associated with the development of AF following CRS-HIPEC, the focus of this study was to investigate technical and other perioperative factors that are associated with AF using a large multi-institutional database. The secondary goal was to describe the incidence of AF as well as its impact on the short- and long-term outcomes of patients undergoing CRS-HIPEC.4
Literature
1.
go back to reference Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI. Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2017;24(4):890–7.CrossRef Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI. Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2017;24(4):890–7.CrossRef
2.
go back to reference McDermott FD, Heeney A, Kelly ME, Steele RJ, Carlson GL, Winter DC. Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg. 2015;102(5):462–79.CrossRef McDermott FD, Heeney A, Kelly ME, Steele RJ, Carlson GL, Winter DC. Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg. 2015;102(5):462–79.CrossRef
3.
go back to reference Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253(5):890–9.CrossRef Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253(5):890–9.CrossRef
5.
go back to reference Jaehne J. Cytoreductive procedures—strategies to reduce postoperative morbidity and management of surgical complications with special emphasis on anastomotic leaks. J Surg Oncol. 2009;100(4):302–5.CrossRef Jaehne J. Cytoreductive procedures—strategies to reduce postoperative morbidity and management of surgical complications with special emphasis on anastomotic leaks. J Surg Oncol. 2009;100(4):302–5.CrossRef
6.
go back to reference Desantis M, Bernard JL, Casanova V, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbeck’s Arch Surg. 2015;400(1):37–48.CrossRef Desantis M, Bernard JL, Casanova V, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbeck’s Arch Surg. 2015;400(1):37–48.CrossRef
7.
go back to reference Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA. Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(8):2152–8.CrossRef Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA. Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(8):2152–8.CrossRef
8.
go back to reference Canda AE, Sokmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1082–7.CrossRef Canda AE, Sokmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1082–7.CrossRef
Metadata
Title
ASO Author Reflections: Impact of Operative Technique on Anastomotic Failure During Cytoreductive Surgery for Peritoneal Malignancies—Surgeon Preference is Fine
Authors
Jason T. Wiseman, MD, MSPH
Jordan M. Cloyd, MD
Publication date
01-03-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-08060-w

Other articles of this Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue